env-c plasmid dna
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2021 (NCT04826094)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04826094 | Phase 1 | Mar 16, 2021 | Kenya Medical Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), The EMMES Corporation, United States Army |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2021 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2021 |
| United States Army | Government | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1